Search Results
Your search for ASCO matches 21353 pages
Showing 18951 - 19000FDA Grants Cobimetinib Priority Review for Use in Combination With Vemurafenib in Advanced Melanoma
The U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review for Genentech’s New Drug Application (NDA) for cobimetinib in combination with vemurafenib (Zelboraf) for the treatment of people with BRAF V600 mutation–positive advanced melanoma. The FDA will make a decision on...
FDA Approves Palbociclib in Combination With Letrozole for Advanced Breast Cancer
The U.S. Food and Drug Administration has granted accelerated approval to palbociclib (Ibrance) in combination with letrozole for the treatment of postmenopausal women with estrogen receptor–positive, HER2-negative metastatic breast cancer who have not yet received an endocrine-based therapy....
Nivolumab in Previously Treated Metastatic Renal Cell Cancer
The approval of multiple inhibitors of either the VEGF or mTOR pathway provided an incremental advance in the treatment of metastatic clear cell renal cancer. However, the agents have several important limitations: For example, the optimal clinical effect appears to be dependent on chronic...
From ASH 2014: What’s New in the Myeloma Treatment Arsenal?
At the 56th American Society of Hematology (ASH) Annual Meeting and Exposition, attendance at many multiple myeloma sessions outnumbered the room size, as data from studies of novel agents, such as the monoclonal antibodies, and from key trials, such as ASPIRE, drew crowds. The ASCO Post covered...
Expert Point of View: Laura A. Dawson, MD
Session moderator Laura A. Dawson, MD, of the University of Toronto, commented on this study by Dr. Ross and colleagues for The ASCO Post: “Moving forward, I think we need to change the way we make treatment decisions, no question. Treatment based on profiling is the way of the future. Dr. Ross’...
Addressing the Global Cancer Burden
Since 1990, the annual global death toll from cancer has risen about 40%, and that number is projected to increase from the current level of approximately 8 million cancer deaths per year to more than 13 million by 2030. The poorer, resource-challenged regions of the world will suffer a...
Big Data and the Promise of Precision Medicine in Cancer
Precision medicine—and its promise to revolutionize how we understand disease and care for our patients—is a concept that oncology has understood and embraced for well over a decade. But millions of Americans recently heard about the concept for the first time when President Obama announced a...
Active Surveillance in Intermediate-Risk Prostate Cancer Called Into Question
A study presented at the 2015 Genitourinary Cancers Symposium calls into question the use of active surveillance in patients with intermediate-risk prostate cancer. Patients with intermediate-risk prostate cancer managed with active surveillance had almost a four times higher risk of prostate...
Caregivers May Want to Know About a Patient’s Impending Death but May Be Afraid to Ask
The likelihood of impending death of patients with advanced cancer “is one of those questions that many people want to know about, but they are too afraid to ask,” David Hui, MD, MSc, said in an interview with The ASCO Post. Dr. Hui is lead author of a study, published in Cancer, on clinical signs...
Recognizing Physical Signs Associated With Impending Death Can Assist Clinicians, Patients, and Caregivers With Complex Decisions
In a recently published study of patients with advanced cancer whose status was systematically documented twice a day, from the time of admission to a palliative care unit until death or discharge, investigators identified eight physical signs associated with death within 3 days. Taken together...
Patient Guides Available Through ASCO University Bookstore
ASCO Answers: Managing the Cost of Cancer Care explains the various costs associated with cancer treatment, including health-care coverage through the Affordable Care Act. It also provides a list of financial resources available to help offset expenses related to care and tips for organizing...
The Center of Who We Are
The following essay by Eric M. Genden, MD, is adapted from The Big Casino: America’s Best Cancer Doctors Share Their Most Powerful Stories, which was coedited by Stan Winokur, MD, and Vincent Coppola and published in May 2014. The book is available on Amazon.com and thebigcasino.org. There’s...
ASCO Commends Dr. Varmus for Outstanding Leadership
Following news of Dr. Varmus’ planned departure from the National Cancer Institute (NCI), ASCO issued the following statement: ASCO is enormously grateful for the service and leadership of Harold Varmus, MD, as Director of the National Cancer Institute [NCI]. During Dr. Varmus’ tenure, the...
Harold Varmus, MD, Steps Down as NCI Director, Douglas Lowy, MD, Named Acting Director
Harold Varmus, MD, who has led the National Cancer Institute (NCI) at the National Institutes of Health (NIH) for nearly 5 years, has announced that he will step down from his post, effective March 31, 2015. “It has been our great fortune to have Dr. Varmus at the helm of the NCI,” said NIH...
2015 Oncology Meetings
MARCH Personalised Cancer Medicine and Big Data Analysis – 7th International Conference of Contemporary OncologyMarch 25-27 • Poznań, Poland For more information: www.termedia.pl/Konferencje?Invitation&e=372&p=2787 Society of Surgical Oncology Annual MeetingMarch 25-28 • Houston, Texas For ...
Dr. Halsted’s Breast Amputation Specimens, Johns Hopkins Hospital, 1894
A Century of Progress The text and photographs on these pages represent the establishment of oncology as a viable medical specialty during the late 1800s and showcase the early medical advances and treatments in cancer. The images and captions are excerpted from a four-volume series of books titled ...
Mobile Patient-Centered App Tracks Breast Cancer Survivors’ Experiences
Patricia Ganz, MD, Director of Cancer Prevention and Control Research at the Jonsson Cancer Center of UCLA, and collaborators Apple and Sage Bionetworks, recently announced the launch of “Share the Journey: Mind, Body and Wellness after Breast Cancer,” a patient-centered mobile application (app)...
Study Finds Websites That Market Personalized Cancer Care Services Overemphasize Benefits
A recent analysis of 55 Internet websites marketing a broad range of tests and services that promise the ability to personalize cancer treatment has found that the websites often overemphasize their purported benefits and downplay their limitations. In addition, the study results show that the...
Fred Hutchinson Health Economist Gary Lyman, MD, MPH, Editor of Recently Released Oncology Handbook
Oncologist and health economist Gary Lyman, MD, MPH, Co-director of the Hutchinson Institute of Cancer Outcomes Research at Fred Hutchinson Cancer Research Center, is the Editor of the second edition of the Oxford American Handbook of Oncology, published February 25, 2015, by Oxford University...
Wrestling With the Challenges of Breast Cancer
Bookmark Title: Then Came Life: Living With Courage, Spirit, and Gratitude After Breast CancerAuthor: Geralyn LucasPublisher: Gotham BooksPublication date: October 2, 2014Price: $19.89; hardcover, 240 pages Over the past decade or so, the oncology community has increased its understanding and...
Medicine Turned Upside Down
BookmarkTitle: The Patient Will See You Now: The Future of Medicine Is in Your HandsAuthor: Eric Topol, MDPublisher: Basic BooksPublication date: January 2015Price: $28.99; hardcover, 384 pagesMost books about health care center on fixing broken parts of the massive $3 trillion system, as seen with ...
Silvia C. Formenti, MD, Appointed Chair of Radiation Oncology at Weill Cornell and Radiation Oncologist-in-Chief at New York-Presbyterian/Weill Cornell
Silvia C. Formenti, MD, has been appointed Chair of the newly established Department of Radiation Oncology at Weill Cornell Medical College and Radiation Oncologist-in-Chief at NewYork-Presbyterian/Weill Cornell Medical Center, effective April 15. Dr. Formenti, currently the Chair of Radiation...
Dinutuximab Combination Approved for Pediatric High-Risk Neuroblastoma
The U.S. Food and Drug Administration (FDA) has approved dinutuximab (Unituxin), a monoclonal antibody targeting glycolipid GD2, as part of first-line therapy for pediatric patients with high-risk neuroblastoma. A chimeric monoclonal antibody that binds to the surface of neuroblastoma cells,...
New Partnership Launches to Empower People Diagnosed With Lymphoma
The Leukemia & Lymphoma Society (LLS), together with the Lymphoma Research Foundation (LRF), CancerCare, the Association of Community Cancer Centers (ACCC), and Genentech announced the launch of a new partnership, the Alliance for Resource Collaboration in Hematology (ARCH). ARCH was developed...
Seattle Children’s Names Jeff Sperring, MD, New Chief Executive Officer
Seattle Children’s Hospital announced that the Board of Trustees has named Jeff Sperring, MD, Chief Executive Officer, effective early in May. Dr. Sperring, who currently serves as President and Chief Executive Officer of Riley Hospital for Children at Indiana University Health, will continue to...
FDA Launches Drug Shortages Mobile App
Today, the U.S. Food and Drug Administration (FDA) launched the agency’s first mobile application (app) specifically designed to speed public access to valuable information about drug shortages. The app identifies current drug shortages, resolved shortages, and discontinuations of drug products....
Five Questions Can Guide the Treatment of Relapsed Myeloma
Joseph Mikhael, MD, MEd, myeloma expert at the Mayo Clinic in Arizona, Scottsdale, and Associate Dean of the Mayo School of Graduate Medical Education, considers five questions when selecting treatment for patients with multiple myeloma who relapse. “With prolonged survival, which approaches 10...
Avoiding Burnout and Maintaining Well-Being While Caring for Seriously Ill Patients
A variety of studies, including one published this past year in the Journal of Clinical Oncology,1 have showed that clinicians who care for seriously ill patients are at high risk for diminished personal well-being, including high rates of burnout; moral distress, defined as the inability to act in ...
ASCO Expresses Concern Over New Oncology Care Model
While commending the Centers for Medicare & Medicaid Services (CMS) for seeking new approaches to physician payment, ASCO expressed concerns over the model’s limited scope. “We are disappointed [CMS has] chosen to pursue only one model—and one that continues to rely on a broken fee-for-service...
New Oncology Care Model: Encouraging Better Coordination for Cancer Care
On February 12, 2015, the U.S. Department of Health and Human Services (HHS) announced its new Oncology Care Model, a multipayer payment and care delivery model intended to support better coordination for cancer care. The initiative will include 24-hour access to practitioners for beneficiaries...
ASCO’s Patient Resources for Colorectal Cancer Awareness Month
Stock your practice with Cancer.Net resources. Cancer.Net has a comprehensive guide to colorectal cancer at www.cancer.net/colorectal and a shorter, one-page colorectal cancer fact sheet. You will also find specialized resources for survivorship, palliative care, and managing the cost of cancer...
Helping Patients Understand Palliative Care
The booklet Palliative Care: Improving Quality of Life for Patients and Families is one of the latest additions to the ASCO Answers collection of patient education materials developed by ASCO for people with cancer and their caregivers. These materials provide oncologist-approved information in a...
Beating the Odds in The Big Casino
More than 35 ASCO members contributed personal essays to a recently published collection of stories about humanism in medicine, including ASCO Past Presidents Paul A. Bunn, Jr, MD, FASCO, and Emil J. Freireich, MD, FASCO, and current President-Elect Julie M. Vose, MD, MBA, FASCO. The Big Casino:...
FDA Takes Steps to Simplify Compassionate Use Process, Invites Comment
The U.S. Food and Drug Administration (FDA) introduced a more streamlined form for requesting permission for patient access to investigational drugs outside of clinical trials. The new form is available for comment in a draft guidance for industry entitled “Individual Patient Expanded Access...
ASCO Supports FDA’s Proposed Regulation of Laboratory Developed Tests
In comments submitted to the U.S. Food and Drug Administration (FDA), ASCO expressed its support for the agency’s draft guidance, “Framework for Regulatory Oversight of Laboratory Developed Tests (LDTs).” ASCO also strongly recommends that the agency proceed with regulatory authority in a way that...
2015 Pre–Annual Meeting Seminars Feature Important Topics for Modern Cancer Care Providers
ASCO will once again be offering a series of Pre–Annual Meeting Seminars ahead of its 2015 Annual Meeting in Chicago. First offered in 2012, the Pre–Annual Meeting Seminars are a series of in-depth educational opportunities dedicated to topics of interest in the oncology community. The seminars are ...
FDA Names Geoffrey Kim, MD, Director of the Division of Oncology Products
The U.S. Food and Drug Administration (FDA) recently announced the appointment of Geoffrey Kim, MD, as Director of the Division of Oncology Products 1 (DOP1) in the Office of Hematology Oncology Products. Dr. Kim assumed this position effective March 22, 2015. Dr. Kim previously served as the...
Development and Approval of Biosimilar Products
INSIDE THE BLACK BOX is an occasional column providing insight into the U.S. Food and Drug Administration (FDA) and its policies and procedures. In this installment, Leah Christl, PhD, and Albert Deisseroth, MD, PhD, answer questions about biosimilar products. Dr. Christl is the Associate Director...
New Lurie Cancer Center Program Combines Oncology With Genomics to Provide More Personalized Cancer Care
The Robert H. Lurie Comprehensive Cancer Center of Northwestern University, in collaboration with the Northwestern Medicine Developmental Therapeutics Institute and Northwestern Memorial Hospital, has launched a new research program, Northwestern Onco-SET (Sequence, Evaluate, Treat). The program’s...
UPMC Whitfield Cancer Centre Receives Joint Commission International Accreditation
For the third time since 2008, the University of Pittsburgh Medical Center (UPMC) Whitfield Cancer Centre, operated by UPMC in Waterford, Ireland, has successfully achieved accreditation from the Joint Commission International (JCI). This recognition is based on an extensive review of the center’s...
Ongoing Controversies in Allocating Our Health‑Care Resources
Disparities of care that result in poorer outcomes among certain populations have long been an issue addressed by the cancer community and its major organizations such as ASCO. While ethnicity and race play key roles in this ongoing debate over equitable allocation of our precious health-care...
Gastric, Breast Cancer Risk in Carriers of CDH1 Gene Mutations
In a new study,1 more precise estimates of age-associated risks of gastric and breast cancer were derived for carriers of the CDH1 gene mutation, a cancer-predisposing gene that is abnormal in families meeting criteria for clinically defined hereditary diffuse gastric cancer (HDGC). David G....
Physician-Controlled Decisions in Cancer Care Linked to Lower Quality Rating
Patients who described physician-controlled decisions about their cancer care vs shared decision-making were less likely to report receiving excellent quality of care, according to a study published by JAMA Oncology.1 The Institute of Medicine has called for shared decision-making and accommodation ...
SOFT Trial Results Inconclusive: Further Study Needed
The results of the SOFT trial—presented at the 2014 San Antonio Breast Cancer Symposium, reported recently by Francis et al in The New England Journal of Medicine,1 and reviewed in this issue of The ASCO Post—were not as conclusive as we had hoped. In essence, the study enrolled women with resected ...
Thyroid Cancer Risk
Women who had breast cancer followed by thyroid cancer were younger on average when diagnosed with their breast cancer than those with breast cancer alone. They also were more likely to have had invasive ductal carcinoma and to have received radiation therapy as part of their breast cancer...
New Analysis Reports Increased Risk of Thyroid Cancer After Breast Cancer Diagnosis
Breast cancer survivors are at increased risk of developing thyroid cancer, especially within 5 years of their breast cancer diagnosis, according to a new analysis of a large national database. The study results were presented at the Endocrine Society’s 97th Annual Meeting.1 “Recognition of this...
Increasing the Use of Hypofractionated Radiation in Early-Stage Breast Cancer: The Way Forward
Bekelman and colleagues are to be congratulated on the publication of an important paper—reviewed in this issue of The ASCO Post—alerting us all to the underutilization of hypofractionated whole-breast irradiation in the treatment of early-stage breast cancer.1 As background, recent randomized...
Expert Point of View: Nancy Kemeny, MD
Nancy Kemeny, MD, Attending Physician at Memorial Sloan Kettering Cancer Center and Professor of Medicine at Weill Cornell Medical College, New York, discussed the study at the session and noted several limitations: The data could be outdated (chemotherapy and surgery could be better now), some...
Priority Review Granted for Trabectedin in Advanced Soft-Tissue Sarcoma
The U.S. Food and Drug Administration (FDA) has granted Priority Review for the New Drug Application (NDA) for trabectedin to treat patients with advanced soft-tissue sarcoma, including liposarcoma and leiomyosarcoma subtypes, who have received prior chemotherapy including an anthracycline. The NDA ...
Winship Cancer Institute of Emory University Names New Chief Medical Officer and Chief Quality Officer
Sagar Lonial, MD, has been named Chief Medical Officer at Winship Cancer Institute of Emory University and Charles A. Staley, MD, has been named Chief Quality Officer, according to an announcement recently released by the Cancer Institute. Both physicians join Winship’s senior leadership team and...
